Moa of sumatriptan?

What is sumatriptan’s MOA (mechanism of action)?

Sumatriptan is a migraine medicine that works as a selective agonist at serotonin (5-HT) 1B and 5-HT1D receptors in cranial blood vessels and trigeminal nerve pathways [1]. By activating these receptors, it causes constriction of dilated intracranial blood vessels and helps reduce the release of pro-inflammatory neuropeptides involved in migraine pain [1].

How does that translate into migraine symptom relief?

Migraine attacks involve activation of trigeminal pathways that amplify pain signaling and inflammation. Sumatriptan’s 5-HT1B/1D receptor activity reduces this signal propagation and vascular changes tied to the attack, which is why it’s used for acute treatment of migraine [1].

What is it used for?

Sumatriptan is used for acute treatment of migraine attacks and may also be used for cluster headaches, depending on the specific formulation and local labeling [1].

Any key safety/clinical implications tied to its MOA?

Because sumatriptan acts on serotonin receptors involved in blood vessel tone, it can have cardiovascular contraindications/precautions in people with certain heart or vascular diseases. This is tied to its vasoconstrictive effects from 5-HT1B receptor activation [1].

Sources

[1] https://www.drugs.com/sumatriptan.html